Should Second-line Aplastic Anemia Drug Be a First-line Option?
A new study published in the New England Journal of Medicine would indicate that eltrombopag should be part of the first-line therapy for aplastic anemia in combination with immunosuppressive therapy.
Thomas Winkler, M.D., staff clinician at NHLBI / NIH explains the pathophysiology and current management of diamond blackfan anemia.
Thomas Winkler, M.D., staff clinician at NHLBI / NIH talks about the use of eltrombopag to possibly treat diamond blackfan anemia.
Cale has Fanconi anemia, an ultra-rare blood disorder. At last count (when he was 7 years old) he had endured over 100 hospital stays and 26 surgeries. He thinks Creighton Blue Jays should win the NCAA tournament this year.
In the latest issue of the New England Journal Medicine, there is a report on the success of Bluebird Bio’s gene therapy for sickle cell disease.
This week in Thrombosis and Haemastasis, Pasi et al report on the long term safety and efficacy of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in patients with severe hemophilia B.
Othon Iliopoulos, MD, of Massachusetts General Hospital describes Von Hippel-Lindau (VHL) Disease and the research his team is doing to better manage this rare condition.
TV and radio personality Alan Colmes died following a brief battle with lymphoma. Mr Colmes was 66 years old. It is uncertain what type of lymphoma he had.
At the 58th ASH meeting in San Diego, CA, we spoke with Dr. Marina Cavazzana PhD about the latest data on bluebird bio’s gene therapy to treat β-thalassemia and sickle cell disease.
Generex Biotechnology plans to buy 51% share of Emmaus Life Sciences, the company that recently submitted an NDA for L-glutamine to treat sickle cell disease.
$vacMongoViewPlus$ $vAR$